Objective
to report the 2-year clinical outcomes of polymer-free biolimus coated stents (Biofreedom) compared to biodegradable polymer sirolimuseluting stents (Orsiro)
Study
prospective, multicentre randomised trial
Population
all-comers
Endpoints
target lesion failure as cardiac death, MI and target lesion revascularisation at 2 years
Conclusion
there were no significant differences in adverse clinical outcomes between stenting with Biofreedom and Orsiro stents at 2-year follow-up
Ellert-Gregerson et al. EuroIntervention. 2022;18:e124-e31
